We have provided evidence indicating that Shp2 knockdown reduces the proliferation and migration of lung cancer cells and that co-inhibition of EGFR and Shp2 can effectively overcome acquired EGFR-TKIs resistance. This evidence concerns the gene PTPN11 and lung cancer.